Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Endo USA Inc., a Keenova Therapeutics Company
Age
37–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients ≥37 years with moderate-to-severe OA related pain in one knee
Body mass index (BMI) ≤40 kg/m2
Symptomatic OA of the index knee diagnosed with a functional capacity of II or III according to ACR criteria classification Note: Patients with symptomatic contralateral knee OA with persistent pain ≤2 cm on a 0-10 cm PI-NRS for ≥2 months will be allowed to participate.
Unchanged dose of analgesic medication for OA for at least 4 weeks prior to screening and for the duration of the study
Able and willing to complete all paper and e-diary assessments required by protocol
You may not be if
Pain in any joint other than the index joint that could interfere with the patient's assessment of pain in the index joint
Compromised integrity of the intact, superficial skin layer
A grade 1 or 4 Kellgren and Lawrence score on radiographic examination
Recent injury to either knee causing pain and interference with daily activities (eg. walking)
Recent surgery/procedure to either knee causing pain that could interfere with study assessments of pain, function, and QoL
Known hypersensitivity or allergy to lidocaine, local anesthetics of the amide type, or any component of the product
Clareo Health | Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee
